文献速递甲状腺疾病

他汀类药物降低新诊断Graves病患者发生眼眶病的风险

Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

主要分析显示未调整HR为0.74(CI 0.65-0.84,P<.001),完全调整后HR为0.87(CI 0.76-1.00,P=.04)。结论提示他汀治疗可能预防新诊断Graves病患者发生GO。

要点

  • 新诊断Graves病患者中使用他汀与眼眶病风险降低相关(完全调整HR 0.87)。
  • 非他汀类降脂药未显示类似保护作用。
  • 主要结果在很大程度上由男性驱动,但性别分层未达统计学显著。

核心结论

  • 在新诊断Graves病患者中,他汀治疗可能预防眼眶病的发生。
  • 建议在临床试验中评估他汀作为新诊断Graves病患者眼眶病预防治疗的效果。

研究设计与样本

  • 多变量分析调整年龄、性别及甲亢治疗。

主要发现

  • 他汀使用者发生GO的风险显著降低:未调整HR 0.74(CI 0.65-0.84,P<.001)。
  • 完全调整后HR为0.87(CI 0.76-1.00,P=.04)。
  • 男性完全调整HR 0.78(CI 0.58-1.04,P=.09),女性HR 0.91(CI 0.79-1.06,P=.24)。
  • 非他汀类降脂药未显示类似的保护效应。
  • 他汀使用者中77.1%使用辛伐他汀,28.9%使用阿托伐他汀,8.2%使用其他他汀。

临床怎么用

  • 对于新诊断Graves病患者,使用他汀可能有助于降低眼眶病发生风险。
  • 非他汀类降脂药未观察到类似保护作用,不应替代他汀用于此目的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT/OBJECTIVE: The aim of this study was to examine the effect of statins and other lipid-lowering agents on the development of Graves orbitopathy (GO) in patients with newly diagnosed Graves disease (GD). METHODS: Our sample included the full adult population of individuals living in Sweden with newly diagnosed GD between 2005 and 2018 (n = 34 894). We compared the GO incidence in statin users (n = 5574) and nonusers (n = 34 409) by applying Cox regression with a time-varying exposure variable. We adjusted for age, sex, and treatment for hyperthyroidism in the multivariate analyses. RESULTS: Periods of nonusage lasted for a median of 4.3 years (interquartile range [IQR] 1.2-8.4), whereas periods of usage lasted for a median of 4.7 years (IQR 2.0-8.1). Among statin users, 77.1% had used simvastatin, 28.9% atorvastatin, and 8.2% had used other statins. Statin users were found to be significantly less likely to develop GO. In the main analysis based on the full cohort, the unadjusted hazard ratio (HR) was 0.74 (CI 0.65-0.84, P < .001), whereas full adjustment altered the effect to 0.87 (CI 0.76-1.00, P = .04). The main results were largely driven by men; the fully adjusted HR was 0.78 (CI 0.58-1.04, P = .09) for men and 0.91 (CI 0.79-1.06, P = .24) for women. Lipid-lowering agents other than statins did not exhibit a similar protective effect. CONCLUSION: In newly diagnosed patients with GD, treatment with statins may protect against the development of GO. Statins should be investigated in a clinical trial as a preventive treatment for GO in newly diagnosed patients with GD.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Nilsson A, Tsoumani K, Planck T, et al. Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease. J Clin Endocrinol Metab. 2021. PMID: 33560351. doi:10.1210/clinem/dgab070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。